US006913768B2

(12) **United States Patent**
Couch et al.

(10) **Patent No.: US 6,913,768 B2**
(45) **Date of Patent: Jul. 5, 2005**

(54) **SUSTAINED RELEASE DELIVERY OF AMPHETAMINE SALTS**

(75) Inventors: **Richard A. Couch**, Bryn Mawr, PA (US); **Beth A. Burnside**, Bethesda, MD (US); **Rong-Kun Chang**, Rockville, MD (US)

(73) Assignee: **Shire Laboratories, Inc.**, Rockville, MD (US)

(*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 115 days.

(21) Appl. No.: **10/353,073**

(22) Filed: **Jan. 29, 2003**

(65) **Prior Publication Data**

US 2004/0059002 A1 Mar. 25, 2004

Related U.S. Application Data

(60) Provisional application No. 60/412,799, filed on Sep. 24, 2002.

(51) **Int. Cl.**[7] **A61K 9/16**; A61K 9/20; A61K 9/22; A61K 9/48; A61K 9/14

(52) **U.S. Cl.** **424/490**; 424/489; 424/494; 424/495; 424/484; 424/486; 424/464; 424/468; 424/451; 424/457

(58) **Field of Search** 424/490, 489, 424/494, 495, 484, 486, 464, 468, 451, 457

(56) **References Cited**

U.S. PATENT DOCUMENTS

4,049,791 A	*	9/1977	Cohen
4,723,958 A		2/1988	Pope et al.
4,728,512 A		3/1988	Mehta et al.
4,765,989 A		8/1988	Wong et al.
4,871,549 A		10/1989	Ueda et al.
4,891,230 A		1/1990	Geoghegan et al.
4,894,240 A		1/1990	Geoghegan et al.
4,902,516 A		2/1990	Korsatko et al.
4,917,899 A		4/1990	Geoghegan et al.
5,002,776 A		3/1991	Geoghegan et al.
5,011,692 A		4/1991	Fujioka et al.
5,011,694 A		4/1991	Nuernberg et al.
5,051,262 A		9/1991	Panoz et al.
5,093,200 A		3/1992	Watanabe et al.
5,156,850 A		10/1992	Wong et al.

(Continued)

FOREIGN PATENT DOCUMENTS

EP	0 212 747	3/1987
GB	768 512 A	2/1957
WO	WO 87/00044	1/1987
WO	WO 90/09168	8/1990
WO	WO 97/03672	2/1997

(Continued)

OTHER PUBLICATIONS

US 6,034,101, 3/2000, Gupta et al. (withdrawn)
Walia et al., Preliminary Evaluation of an Aqueous Wax, Emulsion for Controlled–Release Coating, Pharm. Dev. Tech., vol. 3, No. 1, pp. 103–113 (1998).
Banker et al., Modern Pharmaceutics, eds., Marcel Dekker, Inc., New York, p. 350 (1996).

(Continued)

Primary Examiner—Thurman K. Page
Assistant Examiner—Humera N. Sheikh
(74) *Attorney, Agent, or Firm*—Millen, White, Zelano, Branigan, P.C.

(57) **ABSTRACT**

A pharmaceutical composition comprises a once-a-day sustained release formulation of at least one amphetamine salt which provides mean plasma concentration profile aspects in human ADHD patients which are substantially the same as that provided by ADDERALL XR® type pulsatile formulations.

37 Claims, 13 Drawing Sheets